SCHEMBL324637

SCHEMBL324637

O[C](O)c1ccccc1O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 9/20 0.62
KDM4E B2RXH2 8/20 0.62
ALDH1A1 P00352 6/20 0.62
SMN1; SMN2 Q16637 4/20 0.62
CA12 O43570 2/20 0.62
CA2 P00918 2/20 0.62
CA4 P22748 2/20 0.62
CA14 Q9ULX7 2/20 0.62
CA1 P00915 1/20 0.62
HMGB1 P09429 1/20 0.62
CA6 P23280 1/20 0.62
CA7 P43166 1/20 0.62
CA9 Q16790 1/20 0.62
NAPRT Q6XQN6 1/20 0.62
HSD17B10 Q99714 6/20 0.53
MAPT P10636 4/20 0.53
LMNA P02545 3/20 0.53
NPC1 O15118 2/20 0.53
ALOX15 P16050 2/20 0.53
HIF1A Q16665 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Salicylic Acid SCHEMBL11166419 0.80 ALDH1A1 (0.95) HPGDKDM4EALDH1A1SMN1; SMN2CA12
Salicylic Acid SCHEMBL3778828 0.80 ALDH1A1 (0.95) HPGDKDM4EALDH1A1SMN1; SMN2CA12
SCHEMBL2494549 0.78 HPGD (0.57) HPGDKDM4EALDH1A1SMN1; SMN2CA12
SCHEMBL8498035 0.77 ALDH1A1 (0.58) HPGDKDM4EALDH1A1SMN1; SMN2CA12
SCHEMBL3190837 0.77 HPGD (0.56) HPGDKDM4EALDH1A1SMN1; SMN2CA12
SCHEMBL30043535 0.77 HPGD (0.56) HPGDKDM4EALDH1A1SMN1; SMN2CA12
SCHEMBL61048 0.77 HPGD (0.56) HPGDKDM4EALDH1A1SMN1; SMN2CA12
Salicylic Acid SCHEMBL8433746 0.77 ALDH1A1 (1.00) HPGDKDM4EALDH1A1SMN1; SMN2CA12
Salicylic Acid SCHEMBL1967 0.77 ALDH1A1 (1.00) HPGDKDM4EALDH1A1SMN1; SMN2CA12
Salicylic Acid SCHEMBL1509155 0.77 ALDH1A1 (1.00) HPGDKDM4EALDH1A1SMN1; SMN2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117295704-A Fullerene phosphate polydigalloyl and method 西纳普有限责任公司 2023-12-26 CN claimed
WO-2011085454-A1 GP120 -BINDING BENZENE COMPOUNDS AND SACCHARIDE COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN K.U.LEUVEN R&D (BE) 2011-07-21 WO claimed
EP-1503778-B1 FORMULATION OF A MIXTURE OF FREE-B-RING FLAVONOIDS AND FLAVANS AS A THERAPEUTIC AGENT UNIGEN PHARMACEUTICALS INC (US) 2009-08-05 EP claimed
US-20230148332-A1 VACCINE ADJUVANTS VIROVAX LLC 2023-05-11 US disclosed
EP-4146204-A1 VACCINE ADJUVANTS Virovax LLC (US) 2023-03-15 EP disclosed
US-20230024972-A1 BAKUCHINOYL RETINOATE AND METHODS OF USE THEREOF PHYTO TECH CORP D/B/A/ BLUE CALIFORNIA CO (US) 2023-01-26 US disclosed
WO-2022266493-A1 BAKUCHINOYL RETINOATE AND METHODS OF USE THEREOF PHYTO TECH CORP D/B/A/ BLUE CALIFORNIA CO (US) 2022-12-22 WO disclosed
US-11478411-B2 Use of chelating agents for improving color stability of resorcinol CONOPCO, INC. (US) 2022-10-25 US disclosed
WO-2021226088-A1 VACCINE ADJUVANTS VIROVAX LLC (US) 2021-11-11 WO disclosed
EP-2591082-B1 COMPOSITIONS COMPRISING OPTICAL BENEFIT AGENTS UNILEVER PLC (GB) 2020-11-18 EP disclosed
EP-3558224-B1 USE OF CHELATING AGENTS FOR IMPROVING COLOR STABILITY OF RESORCINOL UNILEVER NV (NL) 2020-04-29 EP disclosed
WO-2001001951-A1 SHEET-LIKE DEVICES THE PROCTER & GAMBLE COMPANY (US) 2001-01-11 WO disclosed
US-6153208-A A WATER INSOLUBLE SUBSTRATE HAVING A SEPARATE CLEANSING AND CONDITIONING PORTIONS WITH DIFFERENT WET EXTENSIBLE, A LATHERING SURFACTANT; DRY WASHCLOTH THE PROCTER & GAMBLE COMPANY (US) 2000-11-28 US disclosed
EP-1011630-A1 CLEANSING AND CONDITIONING ARTICLE FOR SKIN OR HAIR THE PROCTER & GAMBLE COMPANY (US) 2000-06-28 EP disclosed
WO-1999055303-A1 CLEANSING ARTICLES FOR SKIN AND/OR HAIR WHICH ALSO DEPOSITS SKIN CARE ACTIVES THE PROCTER & GAMBLE COMPANY (US) 1999-11-04 WO disclosed
WO-1999013861-A1 CLEANSING AND CONDITIONING ARTICLE FOR SKIN OR HAIR THE PROCTER & GAMBLE COMPANY (US) 1999-03-25 WO disclosed
US-5149884-A Oxidative dehydrogenation of aromatic or aliphatic alcohols in gas phase BASF AKTIENGESELLSCHAFT (DE) 1992-09-22 US disclosed
US-4600740-A Hindered dydroxybenzyl hexaalkyldiphenyl-methanes and stabilized compositions ICI AMERICAS INC. (US) 1986-07-15 US disclosed
US-4224254-A OXIDATION OF AROMATIC ALCOHOLS, SILVER CATALYST BASF AKTIENGESELLSCHAFT (DE) 1980-09-23 US disclosed
US-4200706-A Curing of phenol-formaldehyde resins CONOCO, INC. (US) 1980-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230024972-A1 BAKUCHINOYL RETINOATE AND METHODS OF USE THEREOF RBP4, RARA, RARB HPGD 224/4885KDM4E 791/4885ALDH1A1 227/4885
US-20230148332-A1 VACCINE ADJUVANTS TLR7, TLR8, TLR1 HPGD 3535/4885KDM4E 3968/4885ALDH1A1 4205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.